Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

Exclusion Criteria

• •History or presence of renal artery stenosis
• •Had a functioning renal transplant in the past 5 years and is taking transplant medication
• •Participants in panels A, B and D: Has rapidly fluctuating renal function as determined by historical measurements
• •Has a history gastrointestinal disease which might affect food and drug absorption, as determined by the investigator, or has had gastric bypass or similar surgery
• •History of cancer (malignancy)
• •History of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
• •Has received an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) small molecule treatment, monoclonal antibody, or short interfering RNA (siRNA) or RNA interference (ie, Inclisiran) within 12 months prior to Screening
• •Participants with RI (Panels A, B, and C): Taking medications to treat chronic medical conditions and/or conditions associated with renal disease, if participant has not been on a stable regimen for at least 1 month (other than statins, which require a stable dose for at least 2 months) prior to administration of the initial dose of study intervention, and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 4 hours after administration of study intervention
• •Participated in another investigational study within 4 weeks prior to the prestudy (screening) visit
• •Consumes greater than 3 servings of alcoholic beverages per day
• •Consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day